Sequential versus concurrent anthracyclines and taxanes as adjuvant chemotherapy of early breast cancer: A meta-analysis of phase III randomized control trials

Breast

Volumn 21, Issue 3, 2012, Pages 389-393

  Shao, Nan ^a   Wang, Shenming ^a   Yao, Chen ^a   Xu, Xiangdong ^a   Zhang, Yunjian ^a   Zhang, Yuanyuan ^b   Lin, Ying ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Adjuvant chemotherapy; Concurrent; Early breast cancer; Meta analysis; Sequential

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; TAXANE DERIVATIVE;

ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG FATALITY; EARLY CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART DISEASE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; STOMATITIS; TREATMENT OUTCOME;

EID: 84862528657     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2012.03.011     Document Type: Article

References (27)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC cancer base no. 10 [Internet] 2010, International Agency for Research on Cancer, Lyon, France, Available from:, [accessed 26.12.10]. http://globocan.iarc.fr.
2. Fossati R., Confalonieri C., Torri V., Ghislandi E., Penna A., Pistotti V., et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 1998, 16:3439-3460.
3. Goldhirsch A., Glick J.H., Gelber R.D., Coates A.S., Thürlimann B., Senn H.J., et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005, 16:1569-1583.
4. Ghersi D., Wilken N., Simes R.J. A systematic review of taxane-containing regimens for metastatic breast cancer. Br J Cancer 2005, 93:293-301.
5. Sledge G.W., Neuberg D., Bernardo P., Ingle J.N., Martino S., Rowinsky E.K., et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 2003, 21:588-592.
6. Bria E., Giannarelli D., Felici A., Peters W.P., Nisticò C., Vanni B., et al. Taxanes with anthracyclines as first line chemotherapy for metastatic breast cancer. Cancer 2005, 103:672-679.
7. National Cancer Institute. Dictionary of cancer terms. Available from: 2010; [accessed 26.12.10]. http://www.cancer.gov/dictionary%3fCdrID%3d446564.
8. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
9. Eiermann W., Pienkowski T., Crown J., Chap L., Pawlicki M., Martin M., et al. BCIRG 005 main efficacy analysis: a phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (AC → T) in women with Her-2/neu negative axillary lymph node positive early breast cancer 2008, SABCS 77.
10. Francis P., Crown J., Di Leo A., Buyse M., Balil A., Andersson M., et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: breast International Group 02-98 randomized trial. J Natl Cancer Inst 2008, 100:121-133.
11. Swain S.M., Jeong J.H., Geyer C.E., Costantino J.P., Pajon E.R., Fehrenbacher L., et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 2010, 362:2053-2065.
12. Pestalozzi B.C., Francis P., Quinaux E., Dolci S., Azambuja E., Gelber R.D., et al. Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup phase III BIG 02-98 trial. Ann Oncol 2008, 19:1837-1841.
13. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998, 352:930-942. Early Breast Cancer Trialists' Collaborative Group.
14. De Laurentiis M., Cancello G., D'Agostino D., et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 2008, 26:44-53.
15. Bria E., Nistico C., Cuppone F., Carlini P., Ciccarese M., Milella M., et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer 2006, 106:2337-2344.
16. Von Minckwitz G., Raab G., Caputo A., Schütte M., Hilfrich J., Blohmer J.U., et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 2005, 23:2676-2685.
17. Alba E., Martin M., Ramos M., Adrover E., Balil A., Jara C., et al. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. J Clin Oncol 2004, 22:2587-2593.
18. Conte P.F., Guarneri V., Bruzzi P., Prochilo T., Salvadori B., Bolognesi A., et al. Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma. Cancer 2004, 101:704-712.
19. Martín M., Lluch A., Seguí M.A., Ruiz A., Ramos M., Adrover E., et al. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol 2006, 17:1205-1212.
20. Smith T.J., Khatcheressian J., Lyman G.H., Ozer H., Armitage J.O., Balducci L., et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006, 24:3187-3205.
21. Norton L., Simon R., Brereton H.D., Bogden A.E. Predicting the course of Gompertzian growth. Nature 1976, 264:542-545.
22. Norton L., Simon R. Growth curve of an experimental solid tumor following radiotherapy. J Natl Cancer Inst 1977, 58:1735-1741.
23. Norton L. Evolving concepts in the systemic drug therapy of breast cancer. Semin Oncol 1997, 24(4 Suppl. 10). S10-3-S10-10.
24. Simon R., Norton L. The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens. Nat Clin Pract Oncol 2006, 3:406-407.
25. Norton L., Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986, 70:163-169.
26. Eiermann W., Pienkowski T., Crown J., Sadeghi S., Martin M., Chan A., et al. Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol 2011, 29:3877-3884.
27. National Surgical Adjuvant Breast and Bowel Project Combination chemotherapy in treating women who have undergone surgery for node-positive breast cancer 2004, Available from:, [accessed 26.12.10]. http://clinicaltrials.gov/.